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Introduction
Biological therapies for rheumatoid arthritis (RA) were first approved more than a decade ago (1) The safety and efficacy of intravenous (IV) abatacept have been well established in the global population with both short-term (ST) and long-term studies (3) (4) (5) . IV abatacept is currently approved in several countries, including the USA, and in the European Union, for the treatment of moderate-to-severe RA. In March 2010, IV abatacept also gained approval in Korea.
The clinical development of abatacept is ongoing in Korea. In a ST,169-day study involving Korean patients with RA and an inadequate clinical response to methotrexate (MTX), abatacept improved signs and symptoms, physical function, and patient quality of life and was generally well tolerated (6) .
The long-term extension (LTE), open-label study described here investigated the safety, efficacy, and pharmacodynamic profile of abatacept in patients who had completed the ST study and had received abatacept for an additional 1316 days.
The LTE program aimed to assess the safety of long-term use of abatacept, the efficacy of abatacept and changes in health-related quality of life, and the immunogenicity of abatacept in combination with MTX.
Materials and Methods

Patient population
The study population consisted of Korean patients with active RA who had completed the ST (169-day), double-blind study (ClinicalTrials.gov, NCT00409838). To enter the ST study, patients were required to be Korean, ≥18 years of age, and not pregnant or nursing. Eligible patients met the American Rheumatism Association criteria for RA (7) and the American College of Rheumatology (ACR) functional status of Class I, II, or III RA (8) . Patients also had an initial diagnosis of RA for ＞1 year prior to entering the study. Patients entering the ST study had to present with ≥10 swollen joints (66-joint count), ≥12 tender joints (68-joint count), and C-reactive protein (CRP) levels ≥0.45 mg/dL. Additionally, patients had to have been receiving background MTX treatment (≥15 mg every 7 days) for ≥3 months, with a stable dose for 28 days prior to study entry at Day 1. All other disease-modifying anti-rheumatic drugs (DMARDs), including biologicals, were discontinued ≥28 days prior to Day 1.
Additional permitted concomitant medications in the ST period included oral corticosteroids equivalent to ≤10 mg prednisone daily, with a stable dose for at least 25 of the 28 days prior to treatment initiation on Day 1.
All patients who completed the 169-day, ST, double-blind trial were eligible to be treated with open-label abatacept over IV abatacept was administered at approximately 10 mg/kg (a total of 500 mg for patients weighing ＜60 kg, 750 mg for patients weighing 60∼100 kg, and 1 g for patients weighing ＞100 kg) every 28 days. The background MTX dose could be reduced, discontinued, or increased up to 25 mg weekly. In addition, background corticosteroid therapy could be changed (total equivalent prednisone dose ＞10 mg prohibited) and one DMARD (including parenteral gold, sulfasalazine, chloroquine, hydroxychloroquine, or azathioprine) could be added at the discretion of the investigator based on the patient's clinical status.
Safety assessments
Safety was monitored by recording adverse events (AEs) and were also reported (14) . The Clinical Disease Activity Index (CDAI) and Simplified Disease Activity Index (SDAI) (15) for RA were used to measure disease activity. CDAI is defined as the sum of the tender joint count (28 joints), swollen joint count (28 joints), patient global assessment (0∼10 scale), and physician global assessment (0∼10 scale); SDAI also includes CRP level (mg/dL). Two types of antibodies were detected using two different ELISA methods. The first measured antibody for the whole (beginning of the LTE study) and were subsequently taken biannually during the LTE period. In patients who had discontinued treatment before study termination, samples were also obtained at 28, 56, and 85 days after the last infusion.
To be included in the immunogenicity analysis, patients were also required to have had at least one serum sample collected during the LTE period.
Positive antibody samples confirmed from either ELISA assay which had serum concentrations of abatacept ≤1 μg/mL were further characterized using an in vitro, cell-based bioassay to determine whether the sera contained neutralizing antibody activity. Individual safety and efficacy results associated with antibody response were examined during the LTE period.
Statistical analysis
This LTE was not powered for statistical testing of any pre-defined efficacy hypothesis. Given the descriptive nature of the study, no formal statistical tests were performed. All randomized and treated patients completing the ST study up to Day 169 and receiving ≥1 infusion of abatacept during the LTE study were included in the analysis. Immunogenicity analyses were based on the immunogenicity analysis population, which included all patients who had received ≥1 infusion of abatacept during the LTE period and had ≥1 immunogenicity sample collected during the LTE period.
Results
Patient demographics
A total of 112 patients participated in the ST study; 105 of these patients completed the study and were recruited into the LTE study (ST abatacept cohort: n=53; ST placebo cohort: n=52, Figure 1A ). During the LTE period, 14 patients (13.3%) missed one or two scheduled infusions and 9 (8.6%) missed ≥3 infusions. No patient missed ＞2 consecutive infusions.
A total of 87 patients (82.9%) were still enrolled in the study at the time it was closed due to the approval of abatacept.
Eighteen patients (17.1%) discontinued the study prematurely.
The most common reason for discontinuation was AEs (n=10, 9.5%; Figure 1B ).
The majority of patients who were treated in the LTE study were female (86.7%); the median age at entry into the study (Day 1) was 49.0 years ( Table 1 ). Mean duration of RA among patients entering the LTE study was 9.6 years. During the LTE period, 10 patients (9.5%) were withdrawn from the study due to an AE or multiple AEs (7 neoplasms 
Autoimmune disorders (prespecified)
Autoimmune disorder-related AEs (pre-specified) were reported in 6 patients (5.7%) during the LTE period and up to 56 days after the last infusion of abatacept. Each in- 
Infusion-and injection-related events
Acute infusional AEs were reported in 4 patients (3.8%) and were all mild or moderate in intensity; none were serious and none resulted in discontinuation of treatment. Furthermore, peri-infusional AEs were reported in 17 patients (16.2%) and were mostly mild in intensity. Only 5 of these patients' AEs (4.8%) were considered to be related to study treatment. No infusional AE resulted in treatment discontinuation. One event (arthralgia) was classified as serious but unrelated to study drug.
Clinical efficacy
In the ST abatacept cohort, improvements in disease activity cohort. In the ST placebo group, ACR response rates increased after patients were switched from placebo to open-label abatacept, and were estimated to be similar to those in the ST abatacept group after 84 days on treatment. The improvements were generally maintained in this group through Day 1485. Table 3 and Figure 2 show the ACR response rates during the LTE period by ST treatment cohort.
Disease activity
In the ST abatacept cohort, disease activity measured by the mean change in DAS28 (CRP) score from baseline was reduced (Table   3 ). In both cohorts, the majority of patients who were in remission at Day 169 remained in remission while receiving abatacept during the LTE period, and additional patients in the placebo cohort achieved remission after switching to abatacept (data not shown).
The improvements in SDAI and CDAI scores observed at the end of the ST study were maintained during the LTE period in the ST abatacept cohort. In the ST placebo cohort, there were reductions in CDAI and SDAI; following the switch to open-label abatacept in the LTE period, a larger improvement was observed (Table 3) . These reductions were numerically larger than those achieved in the ST abatacept cohort.
Physical function
In the ST abatacept cohort, the improved KHAQ-DI score observed at the end of Day 169 was maintained until Day 1485 (Table 3 in KHAQ-DI score ≥0.3 units).
Health-related quality of life
In the ST abatacept cohort, the mean improvements in the SF-36 summary and component scores observed at the end of the ST period were maintained during the LTE period. In the ST placebo cohort, there was a small improvement in SF-36 components; following a switch to open-label abatacept in the LTE period, this improvement was larger than that observed in the ST period (Table 3 ). The mean changes in the physical and mental summary measures (PCS and MCS scores) of the SF-36 from baseline over time are summarized in Table 3 . 
Discussion
The ST and long-term safety and efficacy profile of IV abatacept in patients with RA and an inadequate response to MTX is well established in the global population (4, 5) . In addition, the ST study in Korean patients with RA who were inadequate responders to MTX showed that abatacept administered intravenously for up to 169 days was also generally well tolerated and effective (6) .
In this Phase III, LTE, open-label study, it was found that: (4, 18) . The incidences of SAEs, infection/infestation AEs, malignant neoplasms, and autoimmune disorders (pre-specified) found in the LTE study were consistent with those reported in the global long-term study (18) and Korean ST study (6) .
Only one death (cardiac death) was observed during this long follow-up period of 1569 days. This event was reported to be unrelated to study medication. No events of lymphoma or lung cancer were reported in the Korean patients. All except one reported malignant event was resolved with surgery and/or chemotherapy. Serious infections were reported rarely in the study and only two patients discontinued from the study due to an infection-related event.
The incidence of acute infusion AEs observed during the LTE period was low (3.8%); all of these events were mild or moderate in severity and one was classified as unrelated to study treatment. None of these events resulted in discontinuation of study therapy. Infusion-related reactions over such a long period of time were, therefore, rare. Autoimmune events were also rare and none were classified as related to study drug. The clinical laboratory data were generally unremarkable and no safety issues were identified. Interpretation of results should take into consideration the limitations of the study. This study, being an open-label extension, creates a number of challenges for data analysis and interpretation, including bias in outcomes. In addition, the sample size of this study was small; for this reason, the findings of this study alone cannot be generalized to the broader community.
Conclusion
In summary, the safety and efficacy profiles of long-term abatacept treatment (over 1485 days) in Korean patients with RA are favorable and consistent with those found in previous studies. No new safety signals were identified. Additionally, the efficacy profile from the ST study was maintained over the long-term treatment period.
